Wood Gavin's Form 4 filing
Adaptimmune Therapeutics PLCADAPY · filed Sep 3, 2025
- Accession no.
- 0001104659-25-087085
- Filed
- Sep 3, 2025, 5:00 PM ET
- Trade date
- Sep 2, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $950.4. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wood GavinCIK 0001577539 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | Ordinary Shares with a nominal value of GBP0.001 per share | SSaleDisposed | −96,000 | $0.0099F3 | −$950.4 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
Referenced by the price of 1 transaction in Table I.